Sharpest Drug Price Drop in 60+ Years: Inside Trump's Most-Favored-Nation Drug Deals

Introduction

For the first time in more than six decades, American prescription drug prices have fallen sharply — and the White House credits a single policy: Most-Favored-Nation (MFN) pricing. According to the administration, 26 drugmakers have signed deals under the MFN framework, with projected savings of $600 billion.

If those figures hold, it would represent one of the most consequential interventions in the history of American healthcare economics. For decades, the United States has paid the highest drug prices in the world — often several times what patients in other wealthy countries pay for the identical medicine. The MFN policy attacks that disparity at its root: it requires drug companies to sell to Americans at the lowest price they offer anywhere on earth.

This article explains what happened, how Most-Favored-Nation pricing works, what the 26 drugmaker deals involve, and what $600 billion in projected savings would mean for American families.

Background: Why Americans Pay More Than Anyone Else

The Global Price Gap

The same prescription drug, made in the same factory, by the same company, can cost $100 in Canada, $80 in the United Kingdom, and $500 in the United States. This is not an exaggeration or a cherry-picked example — it is the routine, systemic reality of global pharmaceutical pricing.

Other developed countries negotiate drug prices nationally, set price caps, or use their single-payer systems as leverage. The United States, by contrast, has historically let manufacturers set their own prices with minimal government constraint. The result: American patients and taxpayers effectively subsidize lower drug prices for the rest of the world.

Decades of Failed Reform

Politicians of both parties have denounced the price gap for decades. Yet reform repeatedly stalled. The pharmaceutical industry is one of the most powerful lobbies in Washington. Legislation to allow Medicare negotiation or drug importation died in Congress again and again.

The first Trump administration attempted a Most-Favored-Nation rule for Medicare Part B drugs late in its term; it was blocked by federal courts before it could take effect. The Biden administration's Inflation Reduction Act authorized Medicare to negotiate prices for a small, gradually expanding list of drugs — meaningful, but limited in scope.

The current MFN push goes much further, according to the administration: instead of negotiating a handful of drugs through one government program, it seeks to reset the price baseline for the entire American market.

What Is Most-Favored-Nation Pricing?

The Core Idea

The concept is simple and borrowed from international trade. In trade, "most-favored-nation" status means a country must extend to one trading partner the best terms it gives to any. Applied to drugs, it means: the lowest price a drugmaker charges anywhere in the world becomes the price it must offer in the United States.

If a company sells a cancer drug for $2,000 a month in the U.S. but $400 a month in Germany, MFN pricing would require the American price to fall to $400.

How It Works in Practice

According to the administration's description, the MFN policy works through a combination of executive action and negotiated agreements:

1. The requirement is set: The White House establishes that drugmakers must offer MFN pricing to American purchasers or face consequences — which can include tariffs, loss of government contracts, or other regulatory actions.

2. Deals are negotiated: Rather than imposing a single rigid rule, the administration has pursued individual agreements with manufacturers. The White House says 26 drugmakers have signed such deals.

3. Prices reset: Under each deal, the company's American prices move toward the lowest global price for covered drugs.

4. Savings accrue: Lower prices flow through to insurers, government programs, pharmacies, and ultimately patients. The administration projects $600 billion in total savings.

Why Drugmakers Agreed

Pharmaceutical companies did not embrace MFN out of generosity. The administration paired the policy with leverage: the credible threat of tariffs on pharmaceutical imports, regulatory pressure, and the political cost of being seen as gouging American patients.

Faced with that pressure, the White House says, 26 manufacturers chose to negotiate deals rather than fight. Each deal locks in lower American prices in exchange for a more predictable regulatory environment.

The 26 Drugmaker Deals

Scale of the Agreements

The administration reports that 26 drugmakers have signed MFN deals. While the White House has not published the full text of every agreement, the sheer number is significant: it suggests the policy has moved beyond a threat into an operating reality covering a large share of the brand-name drugs Americans take.

Major manufacturers with large American revenues have the most to lose from MFN pricing — and, according to the administration, many of the biggest names are among the signatories.

What's Covered

The deals cover brand-name prescription drugs — the expensive, patent-protected medicines that drive the bulk of American drug spending. Generics, which are already cheap, are less affected. The focus is on the drugs where the global price gap is largest: specialty drugs, biologics, cancer treatments, and widely used chronic-disease medicines.

The $600 Billion Projection

The administration projects $600 billion in savings from the MFN deals. That figure represents the estimated difference between what Americans would have paid at old prices and what they will pay at MFN prices, aggregated across all covered drugs over the projection period.

To grasp the scale: $600 billion is roughly equivalent to several years of total American out-of-pocket prescription spending. If realized, it would be among the largest consumer savings from any single policy in American history.

Supporters note that projections are estimates, not guarantees — actual savings will depend on compliance, enforcement, and how completely MFN prices propagate through the supply chain. But even a fraction of $600 billion would be transformative.

The Sharpest Drop in 60+ Years

What the Data Shows

According to the administration, prescription drug prices have just recorded their sharpest decline in more than 60 years. That is a remarkable claim about a market famous for moving in only one direction: up.

Drug price indexes have ticked upward nearly every year for decades, through recessions, reforms, and changes of administration. A sharp decline — the sharpest in living memory — would mark a genuine break with history.

Why It Matters

Falling drug prices do more than save money at the counter. They:

- Reduce insurance premiums: When drugs cost less, insurers spend less — and premium growth slows.

- Relieve government budgets: Medicare and Medicaid are among the largest drug purchasers in the world. Lower prices mean lower taxpayer costs.

- Improve adherence: Cheaper drugs mean more patients actually take them, reducing expensive hospitalizations.

- Free household budgets: Money not spent on prescriptions can go to food, housing, savings, and everything else families need.

Historical Context

The last time drug prices fell this sharply, Dwight Eisenhower was president. In the intervening 60+ years, the pharmaceutical industry grew into a global behemoth, American healthcare spending ballooned to nearly a fifth of the economy, and the idea that drug prices could actually go down came to seem almost utopian. The administration presents the current decline as proof that determined policy can break even the most entrenched pricing power.

How MFN Affects Different Groups

Patients

For patients, MFN means lower prices at the pharmacy — directly through programs like TrumpRx, and indirectly as lower negotiated prices flow through insurance plans. Patients taking expensive brand-name drugs should see the biggest absolute savings.

Seniors on Medicare

Medicare is the largest single purchaser of prescription drugs in America. MFN pricing on drugs covered by Medicare Parts B and D would reduce both beneficiary cost-sharing and taxpayer spending. The administration has separately announced dramatic GLP-1 price cuts for Medicare beneficiaries — $50 a month — illustrating how MFN principles apply to the senior population.

Employers and Workers

Most working Americans get drug coverage through employer plans. When drug costs fall, employers pay less for health benefits — savings that can flow to workers as slower premium growth, better wages, or richer benefits.

Taxpayers

Medicaid, the VA, federal employee health plans, and other government programs all buy drugs. MFN savings across these programs reduce the federal deficit impact of healthcare spending — a benefit every taxpayer shares.

Real-World Impact: What Lower Prices Look Like

The Patient's Perspective

Consider a patient with rheumatoid arthritis taking a biologic drug priced at $5,000 a month in the U.S. but $1,200 in Europe. Under MFN, the American price moves toward $1,200 — saving that patient (or their insurer) nearly $46,000 a year. Multiply stories like that across millions of patients, and the $600 billion projection starts to look concrete.

The System's Perspective

Lower brand-name prices also change the economics of the whole supply chain. Pharmacy benefit managers, who profit from the spread between list and net prices, face a smaller spread to capture. Insurers redesign formularies around new price realities. Pharmacies see different reimbursement math. The administration argues these knock-on effects compound the direct savings.

Criticisms and Open Questions

What Skeptics Say

No policy of this scale escapes criticism, and fair coverage requires noting the open questions:

- Will savings reach patients? Lower manufacturer prices don't automatically mean lower counter prices. Middlemen could capture some of the difference. The administration's answer is programs like TrumpRx, which deliver discounts directly.

- Will innovation suffer? The industry's longstanding argument is that American prices fund global R&D. If American prices fall to European levels, will research investment decline? Supporters of MFN counter that drug companies remain enormously profitable and that much "innovation" spending goes to marketing and stock buybacks.

- Will companies game the system? Manufacturers could raise foreign prices to narrow the MFN gap, or shift costs in creative ways. Enforcement will determine how much of the projected $600 billion materializes.

- Are the projections reliable? $600 billion is the administration's estimate. Independent analyses will test it over time.

The Administration's Response

The White House's position, as stated in its announcements, is that the sharpest price drop in 60+ years is already happening — not a promise but a measured result. The 26 signed deals, in this framing, are evidence that the policy works: companies are complying, prices are falling, and savings are accruing.

The Global Response: How Other Countries Are Reacting

Foreign Governments Take Notice

The MFN policy has sent ripples through foreign capitals. For decades, other wealthy countries enjoyed low drug prices precisely because America paid high ones — American premiums funded the research, and foreign price controls free-rode on that investment. MFN upends that arrangement.

Some foreign governments have quietly worried that if American prices fall to their levels, drugmakers might raise foreign prices to compensate — or delay launching new drugs in smaller markets. The administration's position is blunt: the free ride is over, and a fairer global distribution of drug costs is long overdue.

The Industry's Global Calculus

Multinational drugmakers now face a genuinely new strategic environment. In the past, they could segment markets: charge America the most, offer moderate prices in Europe, and cut deals in developing countries. MFN collapses those segments into one — the lowest price anywhere becomes the price everywhere that matters.

Industry strategists are reportedly rethinking launch sequencing, foreign pricing, and even which markets to serve. Some analysts predict companies will become more cautious about offering deep discounts abroad, knowing each discount now resets their American price. If that happens, MFN could paradoxically raise some foreign prices — a consequence the administration frames as fairness rather than harm.

A Model for Other Reforms

Health policy experts are watching whether the MFN approach gets applied beyond drugs. The same logic — Americans shouldn't pay the highest price in the world for something sold globally — could theoretically extend to medical devices, hospital services, or other healthcare inputs. The White House has not announced such extensions, but the drug deals have created a template: set the requirement, apply leverage, negotiate compliance.

Frequently Asked Questions

What is Most-Favored-Nation drug pricing?

It's a policy requiring drugmakers to offer Americans the lowest price they charge anywhere in the world. If a drug costs less in another country, the U.S. price must match it.

How many drugmakers have signed MFN deals?

According to the White House, 26 drugmakers have signed deals under the MFN framework.

How much will the deals save?

The administration projects $600 billion in total savings from the MFN agreements.

Have drug prices actually fallen?

The White House says prescription drug prices have seen their sharpest drop in more than 60 years following the MFN deals.

How does MFN affect my prescriptions?

Lower manufacturer prices flow through the system — to insurers, government programs, and direct discount programs like TrumpRx — reducing what patients pay at the pharmacy counter.

Will drug companies stop developing new medicines?

The industry argues high prices fund research; MFN supporters argue companies remain highly profitable and that the U.S. shouldn't subsidize the world's drug costs alone. The long-term innovation impact is debated.

Sources

- The White House — Most-Favored-Nation pricing announcements (administration figures: 26 drugmakers, $600 billion projected savings, sharpest drop in 60+ years)

- Administration statements on prescription drug price trends